Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
نویسندگان
چکیده
منابع مشابه
Appraising adjuvant aromatase inhibitor therapy.
Tamoxifen, once the gold standard adjuvant endocrine therapy for early breast cancer, is being challenged by third-generation aromatase inhibitors (AIs) that have demonstrated improved disease-free survival in a variety of adjuvant settings for early breast cancer. Tamoxifen and AIs have different safety profiles, which should allow physicians to begin to individualize treatment based on a pati...
متن کاملAre another 5 years of adjuvant aromatase inhibitor therapy needed?
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, p...
متن کامل'Fracture incidence after 3 years of aromatase inhibitor therapy'.
BACKGROUND The purpose of this study was to describe the fracture incidence and bone mineral density (BMD) evolution in a large cohort of post-menopausal women with breast cancer after 3 years of aromatase inhibitor (AI) therapy. PATIENTS AND METHODS A prospective, longitudinal study in real-life setting. Each woman had an extensive medical assessment, a biological evaluation, a BMD measureme...
متن کاملPreliminary Data from Ongoing Adjuvant Aromatase Inhibitor Trials I
With recent results showing letrozole and anastrozole to be superior to tamoxifen as initial therapy for advanced disease, the aromatase inhibitors are poised to establish their place in the adjuvant therapy of postmenopausal receptorpositive breast cancer. A review of the rationale, design, and prel iminary results of the ongoing adjuvant trials that include aromatase inhibitors will be presen...
متن کاملManagement of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
Treatment with aromatase inhibitors for postmenopausal women with breast cancer has been shown to reduce or obviate invasive procedures such as hysteroscopy or curettage associated with tamoxifen-induced endometrial abnormalities. The side effect of upfront aromatase inhibitors, diminished estrogen synthesis, is similar to that seen with the natural events of aging. The consequences often inclu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2016
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa1604700